Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2023-04-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞第二届董事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes approvals of various reports and proposals related to the 2022 annual report, board work report, audit committee report, financial statements, budget, internal control evaluation, profit distribution, remuneration plans, appointment of auditors, and other corporate governance matters. The document repeatedly states that the detailed contents of these reports are disclosed elsewhere on the Shanghai Stock Exchange website, indicating this document itself is not the full annual report or financial statements but a board meeting resolution announcement. It also includes appointment of a new CFO and changes in company structure. The document is about board decisions and management information rather than the full annual report or audit report. Therefore, the best fitting category is Board/Management Information (MANG). The document length is under 5,000 characters, but it contains substantive board meeting resolutions, not just a brief announcement of a report publication, so it is not RPA. Hence, classification is MANG with high confidence.
2023-04-25 Chinese
神州细胞关于续聘公司2023年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2023. It details the qualifications, independence, and audit fees of the proposed audit firm, PwC Zhongtian, and describes the approval process by the audit committee, independent directors, and the board of directors. The document does not contain any financial statements or audit reports themselves but is a formal notice about the appointment of the audit firm to conduct the audit for the upcoming fiscal year. The document length is 3528 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of an Audit Report / Information announcement about the audit firm appointment, not the audit report itself. FY 2023
2023-04-25 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2023年度申请综合授信额度并提供担保的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding Beijing Shenzhou Cell Biotechnology Group Co., Ltd.'s 2023 application for a comprehensive credit limit and provision of guarantees. It includes information about the credit application, guarantee details, internal decision procedures, financial data, board and independent directors' opinions, and the sponsor's opinion. The document is not a full financial report but rather a formal opinion and verification related to financing and guarantees. It does not contain quarterly or annual financial statements or earnings highlights, nor is it a simple announcement or certification. The content focuses on financing activities and guarantees, which aligns with a Capital/Financing Update filing type.
2023-04-25 Chinese
关于神州细胞非经营性资金占用及其他关联资金往来情况汇总表的专项审计报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计报告" which translates to a "special audit report" concerning non-operating fund occupation and other related party fund transactions for the year 2022. It is prepared by an audit firm (PwC Zhongtian) and includes detailed tables of financial data related to these transactions. The content is focused on audit findings and financial details related to specific audit areas rather than a full annual report or general financial statements. The document length is 1445 characters, which is relatively short but contains substantive audit information rather than just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles excluding full annual reports. FY 2022
2023-04-25 Chinese
神州细胞2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. during the year 2022. It includes specifics on the amounts raised through initial public offerings and private placements, the use of these funds, balances, cash management, and compliance with regulatory requirements. It also contains auditor and sponsor opinions on the proper use of the funds. The document references regulatory guidelines related to the management and use of raised funds and provides detailed tables on fund usage and balances. This type of document is a specialized report on fundraising and capital usage, which aligns with the category 'Capital/Financing Update (CAP)' rather than a general annual report or audit report. The document length is substantial and contains actual financial data and analysis related to capital raising and fund usage, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-04-25 Chinese
神州细胞2022年年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" which translates to "2022 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, risk factors, governance, and audited financial statements. The presence of an audit report by PwC and signatures from company officers further confirms this is a full annual report. The document length is substantial (15,000 characters), and it includes comprehensive financial and operational information for the fiscal year 2022. There is no indication that this is merely an announcement or a summary; it is the full report itself. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2023-04-25 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.